## HUNTSMA N Enrichin g live s throug h innovatio n 

## RECEIVE D OPP TCBI C 20I3MA Y2 1 PH6--0

0

May17 , 201 3 

## OPPT-2011-018 2 By : EMAI L an d FEDE X Ms . Katherin e Sleasma n U.S . EP A 120 0 Pennsylvani a Ave . N W Mai l Cod e 7405 M Washingto n D C 2046 0 Tel : 202-564-771 6 email : sleasman.katherine@epa.go v Dea rMs . Sleasman : A s requested , attache d i s a sanitize d versio n o f th e Substantiatio n Question s t o accompan yCB I informatio n submitte d i n respons e t o EPA' s Voluntar yinformatio n Reques t fo rInformatio n Relatin g t o Curin g Rate s fo rPolyurethane s Products" . Sincerely , Monic a Karamag i ( j Regiona l Marketin g an d Industr yAffair s Manage r Enclosur e

6 3 1 30000035/ S 

## Compan ySanitize d 1000 3 Woodloc h Fores t Drive , Th e Woodlands , Texa

s 7738 0 j Tel. : 281-719-600

0 Fax. : 281-719-641 6 www.huntsman.com i 8QNNNSD& INDEXE D ' BY : PAUL Ap . 2

Response s to th e Substantiatio n Question s to accompan y Compan y Confidentia l documen t title d "Huntsma n Internationa l LLC' s Respons e t o EPA' s Voluntary Informatio n Reques t fo rInformatio n Relatin g to Curin g Rate s fo rPolvurethane s Products" . 1 . I s you rcompan yassertin g thi s confidentia l busines s informatio n (CBI ) clai m o n it s ow n behalf ? I fth e answe ri s no , pleas e provid e compan yname , addres s an d telephon e numbe ro fentit yassertin g claim . Ye s 2 . Fo rwha t perio d d o yo u asser t you rclaim(s ) o f confidentiality ? I f th e clai m i s t o exten d unti l a certai n even t o rpoin t i n time , pleas e indicat e tha t even t o rtim e period . Explai n wh ysuc h informatio n shoul d remai n confidentia l unti l suc h point . W e are requestin g that thi s informatio n b e hel d confidentia l indefinitely , 3 . Ha s th e informatio n that yo u ar e claimin g as confidentia l bee n disclose d t o an y othe rgovernmenta l agency , o rt o thi s Agencya t an yothe rtime ? No . 4 . Briefl ydescrib e an yphysica l o rprocedura l restriction s withi n you rcompan y relatin g t o th e us e an d storag e o fth e informatio n yo u are claimin g CBI .

5 . I fanyon e outsid e you rcompan yha s acces s t o an yo f th e informatio n claime d CBI , ar e the yrestricte d b yconfidentialityagreement(s) . I fso , explai n th e conten t o fth e agreement(s) . 6 . Doe s th e informatio n claime d a s confidentia l appea ro ri s i t referre d to i n an yo f th e following : a . Advertisin g o rpromotiona l materia l fo rth e chemica l substanc e o rth e resultin g an d product ; N o b . Materia l safetydat a sheet s o rothe rsimila rmaterial s (suc h a s technica l dat a sheets ) fo rth e substanc e o rresultin g en d product (includ e copie s o f thi s informatio n a s i t appears whe n accompanyin g th e substanc e and/o rproduct at th e tim e o ftransfe ro rsale) ; N o c . Professiona l o rtrad e publications ; N o o r



## Compan y Sanitize dp . 3

d . An yothe rmedi a o rpublication s availabl e t o th e publi co rt o you r competitors . N o I f yo u answere d ye s t o an yo f th e above , indicat e wher e th e informatio n appears , includ e copies , an d explai n wh yi t shoul d nonetheles s b e treate d a s confidential . 7 . Ha s EPA , anothe rfedera l agency , o rcour t mad e an yconfidentiality determinatio n regardin g informatio n associate d wit h thi s substance ? I f so , provid e copie s o fsuc h determinations . N o 8 . Describ e th e substantia l harmfu l effect s tha t woul d resul t t o you rcompetitiv e positio n i fth e CB I informatio n i s mad e availabl e t o th e public ? I n you ranswer , explai n th e causa l relationshi p betwee n disclosur e an d an yresultin g substantia l harmfu l effects . Conside ri n you ranswe rsuc h constraint s a s capita l an d marketin g cost , specialize d technica l expertise , o runusua l processe s an d you r

9 . Has th e substanc e bee n patente d i n th e U.S . o relsewhere ? I s a paten t fo rth e substanc e currentl ypending ? N o 10 , I s thi s substance/product commerciall yavailabl e an d i fso , fo rho wlon g has i t bee n availabl e o n th e commercia l market ? Yes . Huntsma n ha s bee n sellin g MD I sinc e 1999 . Th e predecessor , ICI , ha s bee n sellin g MD I i n America s regio n sinc e 1978 . a . I fo n th e commercia l market , ar e you rcompetitors aware tha t th e substanc e i s commerciall yavailabl e i n th e U.S. ? Ye s b . I fnot alread ycommerciall yavailable , describ e wha t stag e o fresearc h an d developmen t (R&D ) th e substanc e i s in , an d estimat e bowsoo n a marke t wil l b e established . N/

A

Pag e 2 o f3p . 4



### 11 . c . Wha t i s th e substanc e use d fo ran d wha t typ e o f product(s ) doe s i t appea r in . MDI , methylen e dipheny l diisocyanat e i s use d t o produc e a wid e variety o fcommercia l availabl e polyurethan e product s e.g. , rigi d polyurethan e foa m fo rinsulation , composit e woo d binders , automotiv e seating , furniture , bedding , applianc e insulatio n etc . Describ e whethe ra competito rcoul d empio> recreat e th e substance ? t o identica l

12 . D o yo u asser

t tha t disclosur e o f thi s informatio n yo u ar e claimin g CB I woul d reveal : a . confidentia l processe s use d i n manufacturin g th e substance ; Ye s - confidentia l formula s are liste d i n som e case s b . i fa mixture , th e actua l portion s o f th e substanc e i n th e mixture ; Ye s - se e abov e o r c . informatio n unrelate d t o th e effect s o fth e substanc e o n huma n healt h o rth e environment ? Yes , th e confidentia l informatio n i s unrelate d t o huma n healt h o renvironmenta l effects . I fyou ranswe rt o an yo fth e abov e question s i s yes , explai n howsuc h informatio n woul d b e revealed . Chemica l formula s an d custome ridentitie s ar e disclose d i n man ycases . 13 . Provid e th e Chemica l Abstract Servic e Registr yNumbe rfo rth e product , i f known . I s you rcompan yapplyin g fo ra CAS numbe rnowo ri n th e nea rfuture ? I fyo u hav e applie d fo ra CA S number , includ e a cop yo f th e contract wit h CAS . N o MDI-101-68- 8 Polymeri cMD I - 9016-87- 9 14 . I s th e substanc e o ran yinformatio n claime d CB I th e subject o f FIFRA regulatio n o rreporting ? I f so , explain . N o

Pag e 3 o f3p . 5

Moseley , Pamel a From : Sent : To : Subject : Attachments : Sleasman , Katherin e Monday , Ma y20 , 201 3 9:2 7 A M Moseley , Pamel a FW : Huntsma n Internationa l LLC' s Sanitize d Versio n o fth e Substantiatio n Questions - Docke t

- EPA-HQ-OPPT-2011-018 2 Sanitize d Versio n o fth e Substantiatio n Questions.pd f FY l - Fo ryou rrecords . -Katherin e from : Michell e M Koeni g rmailto:michell e m koenia@huntsman.com ] Sent : Friday , Ma

y17 , 201 3 6:0 7 P M To : Sleasman , Katherin e Cc : Monica N Karamag i Subject : Huntsma n Internationa l LLC' s Sanitize d Versio n o fth e Substantiatio n Question s Submitte d o n behal f o f Monic a Karamagi of Huntsma n Internationa l LLC .

l